Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MAVENCLAD vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
FDA: Treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease.
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life of cladribine is approximately 5.7 days (range 4-10 days) following oral administration. This long half-life supports once-daily high-dose short-course dosing and is due to slow release from lymphocytes. Clinical context: Allows sustained intracellular levels of active triphosphate in lymphocytes.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate metabolite. It is also phosphorylated by other nucleoside kinases. The elimination half-life is approximately 1 day. Renal excretion of unchanged drug accounts for about 18% of the dose.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Approximately 100% of cladribine dose is eliminated via renal excretion of unchanged drug and metabolites, with <5% recovered in feces. Renal clearance is about 2/3 of total clearance. Biliary elimination is negligible.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
20% bound to plasma proteins, primarily albumin. No significant binding to alpha1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
Apparent volume of distribution is approximately 4.3 L/kg (range 1-9 L/kg). This large Vd indicates extensive extravascular distribution, including penetration into cells and tissues, particularly lymphocytes. Clinical meaning: High tissue distribution correlates with intracellular loading in target immune cells.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability of cladribine from MAVENCLAD is approximately 40% (range 30-50%). It is converted to active triphosphate intracellularly, so prodrug absorption is similar. Food reduces absorption by ~20% but does not affect clinical effect.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
Contraindicated in patients with estimated GFR <30 m L/min/1.73 m2 due to potential accumulation and increased risk of adverse reactions. No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73 m2).
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh class B or C). No dose adjustment recommended for mild hepatic impairment (Child-Pugh class A).
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Not approved for use in pediatric patients less than 18 years of age. Safety and efficacy have not been established.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended based on age alone. However, renal function should be assessed and dosing should be based on e GFR as in younger adults. Experience in patients over 60 years of age is limited.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
WARNING: MALIGNANCIES. Cladribine can increase the risk of malignancies (including cases of cancer-related deaths). Because of this risk, MAVENCLAD should be used in patients who have had an inadequate response to, or are unable to tolerate, other drugs indicated for the treatment of MS.
None.
Risk of malignancies: including treatment-emergent malignancies (e.g., cancers of the lung, gastrointestinal tract, skin, breast, and others).,Hematologic toxicity: severe bone marrow suppression (thrombocytopenia, anemia, neutropenia); monitor CBC counts before and during treatment.,Infections: increased risk of serious infections, including opportunistic infections (e.g., tuberculosis, herpes zoster, progressive multifocal leukoencephalopathy); screen for latent infections before initiation.,Hepatic injury: cases of drug-induced liver injury; monitor liver enzymes.,Fetal risk: can cause fetal harm; advise females of reproductive potential to use effective contraception during and for 6 months after the last dose.,Vaccinations: avoid live vaccines during and after treatment.,Impaired renal function: use with caution; cladribine pharmacokinetics may be altered.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Current malignancy.,Patients with HIV infection.,Active chronic infections (e.g., tuberculosis, hepatitis).,Hypersensitivity to cladribine or any component of the formulation.,Women who are pregnant or breastfeeding.,Concomitant use with other immunosuppressive or myelosuppressive therapies (except corticosteroids for acute exacerbations).
Hypersensitivity to AURLUMYN or any of its components.
No significant food interactions reported. Avoid grapefruit and grapefruit juice as they may alter drug metabolism.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of fetal harm, including teratogenicity and embryolethality. In humans, no adequate controlled studies exist; therefore, use in all trimesters is contraindicated. Women of childbearing potential must use effective contraception during treatment and for at least 6 months after the last dose.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
It is unknown whether cladribine is excreted in human breast milk. However, due to the potential for serious adverse reactions in nursing infants and the drug's long half-life, breastfeeding is not recommended during treatment and for at least 10 days after the last dose. M/P ratio is not available.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
MAVENCLAD is contraindicated in pregnancy and should not be used. No dosing adjustments are applicable as the drug is not to be administered to pregnant women.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Mavenclad (cladribine) is an oral purine antimetabolite approved for relapsing multiple sclerosis. It is given as two short courses per year for two years. Monitor for lymphopenia, infections, and malignancies. Contraindicated in patients with active infections or current malignancy. Do not use in patients with HIV or hepatitis B/C. Live vaccines contraindicated during and after treatment. Pregnancy category D; effective contraception required. Monitor liver enzymes and bilirubin. Consider PCP and VZV prophylaxis if lymphopenia severe. MRI monitoring for PML is recommended.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Mavenclad is taken in two treatment courses per year, each consisting of 4 or 5 days of tablets, for 2 years.,You need regular blood tests to monitor your white blood cell count, liver function, and for infections.,Avoid live vaccines during treatment and for at least 1 year after the last dose.,Use effective contraception during treatment and for at least 6 months after the last dose.,Report any signs of infection (fever, chills, cough), unusual bleeding, or easy bruising immediately.,Do not take Mavenclad if you have an active infection, cancer, or HIV/hepatitis B or C.,Avoid grapefruit products during treatment.,Store tablets at room temperature away from moisture.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MAVENCLAD vs AURLUMYN, answered by our medical review team.
MAVENCLAD is a Antineoplastic Agent that works by Cladribine is a prodrug that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to lymphocyte depletion. It selectively targets and reduces circulating T and B lymphocytes, thereby modulating the immune response in multiple sclerosis.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MAVENCLAD and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MAVENCLAD is: 3.5 mg/kg body weight administered orally as two treatment courses of 1.75 mg/kg each over two consecutive weeks (cumulative dose 3.5 mg/kg per year). Each course is given as a 14-day period: 1.75 mg/kg in divided doses daily for 4 or 5 days, depending on patient preference (e.g., 10 mg tablets daily for that period).. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MAVENCLAD and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MAVENCLAD is classified as Category C. MAVENCLAD (cladribine) is contraindicated in pregnancy. Based on animal studies and its mechanism of action (cytotoxicity to rapidly dividing cells), there is an increased risk of . AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.